Acrivon Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $19.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on the promising developments in Acrivon Therapeutics, Inc.’s pipeline, particularly the ACR-368 Phase 2b trial. The company has initiated a third cohort that includes all-comers, which addresses a significant limitation of the previous biomarker-selected strategy by not requiring a pre-treatment biopsy. This approach is expected to enhance enrollment speed and convenience, potentially leading to a higher overall response rate (ORR) due to the inclusion of less heavily pre-treated patients and the use of ultra low-dose gemcitabine (ULDG) across both biomarker-positive and biomarker-negative patients.
Furthermore, the anticipated update in the fourth quarter of 2025 is expected to provide insights into the confirmatory trial plans and the initial experiences with the new cohort. The previous data has shown encouraging results, with a 35% confirmed ORR in biomarker-positive patients, suggesting a potential superiority over standard chemotherapy. The elimination of the biopsy requirement in the third cohort could significantly improve enrollment rates, supporting a broader, diagnostic-free label for ACR-368 if the outcomes are positive. These factors contribute to the optimistic outlook and the Buy rating for Acrivon Therapeutics, Inc.
In another report released on November 14, Oppenheimer also reiterated a Buy rating on the stock with a $8.00 price target.